Overview

Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)

Status:
Terminated

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.

Phase:

Phase 2

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

Docetaxel